NTRK1 and gastrointestinal stromal tumor: Especially, since activating mutations in KIT proto-oncogene receptor tyrosine kinase or in platelet-derived growth factor alpha are considered major drivers of GIST and their detection predicts treatment responsiveness or resistance (Joensuu et al. 2017).